drugset / Trial / NCT07068295

A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump

NCT07068295

Phase 1 Completed 65 enrolled Novo Nordisk A/S
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The study will last for about 13-67 days (or a half to 2 months).

Timeline

Start
2025-07-11
Primary completion
2026-02-22
Completion
2026-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0471-0119 H Protein / enzyme biologic Subcutaneous
Subject insulin aspart Protein / enzyme biologic Subcutaneous